Financial PositionThe company has a strong cash position with $317.3 million in cash and cash equivalents, providing a cash runway into 2027.
Pipeline DevelopmentImmunome is building an incredibly robust ADC pipeline with one in the clinic (1021) and several more.
Product CommercializationThe company intends on commercializing varegacestat in the US, Canada, and Europe, with external distributors in LATAM and Middle East, as well as partner(s) in Asia.